We ended the quarter with unrestricted cash and cash equivalents of approximately $26.2 million, however, our cash and cash equivalent at the end of June will not be sufficient to fund our operation for the 12-month period following such date. And as a result, our second quarter financial statement, contained a footnote, disclosing material uncertainties related to events and conditions that may cast substantial doubts about our ability to continue as a going concern for at least one year from June 30, 2016. We expect to address the situation before the end of the year.
Aug. 10, 2016 1:38 PM ET
Thanks, Jason. It’s a logic question. The response to that question is not that straight forward, because the achievement of the 384 event not only depends on the last treatment, it also depends on when particular patients are enrolled. It’s not that all of the patients were enrolled at the same time, but it was rather an enrollment over a period of approximately one to two years. So it’s very difficult to come up with an estimation on when the achievement would have been achieved, if both treatments has been equal.
We obviously have done our calculations and we have observed the event rate from the very beginning, and based on that - as David already stated, based on that the event-rate slowed down. And now you can come up with a lot of speculations and at these days there may be many reasons to explain it. We actually tend to feel positive about it and as you are very well aware this is a fact that you can observe in quite a variety of different oncology trials with overall survival at a particular endpoint.
So in other words, we see a prolongation of what we have initially planned; this is a slower event-rate. Obviously, a longer survival rate as we initially planned. And now we just have to wait and see until we reach the 384 events.
Die freuen sich schon auf Zoptrex.
Zoptarelin doxorubicin for locally advanced, recurrent or metastatic endometrial cancer — second line
Bezug auf OS und PFS.
The median time from primary treatment to disease relapse (PFI-1) was 6.7 months. Thirty-one percent of these recurrent patients received platinum-based chemotherapy for second-line treatment. When PFI-1 and type of second-line therapy, along with race, PS, stage, grade, and prior RT were included for analysis, PFI-1 became the most significant factor predictive of survival after recurrence; race, PS, stage, grade, and prior RT remained significant. Compared with patients with a PFI-1 ≤6 months, those with PFI-1 >6 months had a 30% reduction in the risk of death (HR, 0.70; 95% CI, 0.59-0.84 [P < .0001]). There was no evidence that the type of second-line therapy (platinum vs nonplatinum) was associated with survival (HR, 0.92; 95% CI, 0.77-1.11 [P = .392])(Table 3). Furthermore, when we restricted the analysis to patients who had primary treatment with platinum-based chemotherapy (n = 483), the results were essentially the same.
Auch mal in die einzelnen Studien schauen!
|3,20 €||+2,24%||3,13 €||0||350||-||12.08.16|
|3,219 €||+0,50%||3,203 €||-||-||3,203 - 3,246||14:00:16|
|3,13 €||0,00%||3,13 €||0||0||-||05.08.16|
|3,61 $||+1,98%||3,54 $||0||111.263||-||12.08.16|
|3,24 €||+1,57%||3,19 €||300||2.300||3,174 - 3,26||11:09:55|
|3,13 €||G||-0,82%||3,156 €||0||0||3,13 - 3,133||09:10:43|
|3,154 €||G||+1,64%||3,103 €||0||0||3,154 - 3,154||08:37:19|
|Wertung||Antworten||Thema||Verfasser||letzter Verfasser||letzter Beitrag|
|23||14.477||Aeterna nach dem Split||Heron||Heron||13:24|
|9||9.861||AEZS vs. KERX||Gropius||ammut1||22.08.19 16:23|
|21||7.679||Aeterna Zentaris Inc.||Heron||Heron||07.08.19 12:43|
|3||Chart 01.12.2018||Aktienflüsterin||Heron||27.01.19 19:01|
|6||2.883||AEZS Transformation zum Big Player||boreas||paioneer||01.12.18 20:08|